283. 後天性赤芽球癆 [臨床試験数:17,薬物数:36(DrugBank:19),標的遺伝子数:16,標的パスウェイ数:91

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04470804
(ClinicalTrials.gov)
August 1, 20209/7/2020Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCASirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective StudyPure Red Cell Aplasia, AcquiredDrug: Sirolimus;Drug: Cyclosporine ABing HanNULLNot yet recruiting18 Years70 YearsAll40Phase 4China
2NCT01288131
(ClinicalTrials.gov)
January 20091/2/2011Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) TreatmentRandomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and PrednisoloneAnti-r-HuEpo Associated PRCA SubjectsDrug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + predChulalongkorn UniversityNULLTerminated18 Years60 YearsBoth8Phase 3Thailand